Sugi Predict

Sugi Predict / Compounds / SCHEMBL5283079

SCHEMBL5283079

SCHEMBL5283079

NC(Cc1c(F)c(F)c(O)c(F)c1F)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ CYP2C9 P11712 3/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ BLM P54132 3/20 0.47
▸ PKM P14618 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ HIF1A Q16665 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ RECQL P46063 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ RGS12 O14924 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ BRCA1 P38398 1/20 0.47
▸ THPO P40225 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324038 1.00 USP2 (0.47) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL5282915 0.94 USP2 (0.46) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL158168 0.90 MAPT (0.47) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL4626004 0.90 MAPT (0.47) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL43843 0.90 MAPT (0.47) USP2MAPTCYP2C9MEN1KMT2A
Tyrosine SCHEMBL28251306 0.86 SLC7A5 (0.71) USP2KDM4EPKMALDH1A1ALOX15
SCHEMBL2971635 0.82 GRIA1 (0.47) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL2971633 0.82 GRIA1 (0.47) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL13205282 0.79 TSHR (0.42) USP2MAPTCYP2C9MEN1KMT2A
SCHEMBL5285947 0.78 USP2 (0.50) USP2MAPTCYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382646-A1 ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-12-18 — — US claimed
US-12421534-B2 Engineered enzymes and method for the synthesis of diverse tyrosine analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-09-23 — — US claimed
US-20230313245-A1 Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-10-05 — — US claimed
WO-2023086520-A2 ENGINEERED ENZYMES AND METHOD FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-05-19 — — WO claimed
CN-109295025-B Tyrosine analogue translation system and gene-encoded protein photoinduced electron transfer fluorescence sensor protein family 中国科学院生物物理研究所 2021-04-02 — — CN claimed
CN-109295025-A The protein photo induced electron transfer fluorescent optical sensor protein family of Tyrosine Analogues translation system and gene coding 中国科学院生物物理研究所 2019-02-01 — — CN claimed
CN-105420203-A Tyrosine analogue translation system and gene-encoded protein photoinduced electron transfer fluorescence sensor protein family INST OF BIOPHYSICS CHINESE ACAD OF SCIENCES 2016-03-23 — — CN claimed
US-7265146-B2 Integrin receptor inhibitors GENENTECH, INC. (US) 2007-09-04 — — US claimed
US-20050187284-A1 Integrin receptor inhibitors GENENTECH, INC. (US) 2005-08-25 — — US claimed
EP-1330430-A2 INTEGRIN RECEPTOR INHIBITORS GENENTECH, INC. (US) 2003-07-30 — — EP claimed
US-20020035104-A1 Integrin receptor inhibitors GENENTECH, INC. 2002-03-21 — — US claimed
WO-2002016313-A2 INTEGRIN RECEPTOR INHIBITORS GENENTECH, INC. (US) 2002-02-28 — — WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
WO-1994011392-A1 PEPTIDE INHIBITORS OF TYROSINE KINASES AND THERAPEUTIC USES THEREOF WARNER-LAMBERT COMPANY (US) 1994-05-26 — — WO claimed
US-20250382646-A1 ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-12-18 — — US disclosed
US-12421534-B2 Engineered enzymes and method for the synthesis of diverse tyrosine analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-09-23 — — US disclosed
US-20230313245-A1 Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-10-05 — — US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 — — EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed
WO-1994011392-A1 PEPTIDE INHIBITORS OF TYROSINE KINASES AND THERAPEUTIC USES THEREOF WARNER-LAMBERT COMPANY (US) 1994-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035104-A1 Integrin receptor inhibitors ITGB1, ITGA1, ITGA4 USP2 4817/4885MAPT 4730/4885CYP2C9 3887/4885
US-20050187284-A1 Integrin receptor inhibitors ITGA4, ITGB4, ITGB1 USP2 4796/4885MAPT 4495/4885CYP2C9 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.